NLS Pharmaceutics AG

NLS Pharmaceutics AG is a biopharmaceutical firm currently in its clinical development phase, concentrating on identifying and advancing therapeutic interventions for individuals affected by complex and uncommon conditions impacting the central nervous system (CNS). The company's research and development primarily target narcolepsy, idiopathic hypersomnia, and various other infrequent sleep disorders, alongside neurodevelopmental conditions like attention deficit hyperactivity disorder (ADHD). Key product candidates in their pipeline include Quilience, designed to alleviate excessive daytime drowsiness and cataplexy, and Nolazol, which aims to treat ADHD. Additionally, NLS Pharmaceutics is progressing several other compounds: NLS-4, a selective dopamine reuptake inhibitor for rare sleep disorders; NLS-3, a repurposed methylphenidate ester for ADHD treatment; and NLS-8, a melatonin ML1A receptor agonist that has shown promise in improving scopolamine-induced amnesia. Their portfolio also features NLS-11, a norepinephrine and dopamine reuptake inhibitor with muscarinic M1, M2, M3 receptor antagonist properties, and NLS-12, another norepinephrine and dopamine reuptake inhibitor that functions as a muscarinic M4 receptor antagonist. Established in 2015, NLS Pharmaceutics AG is headquartered in Zurich, Switzerland.